Table 2.
Ongoing trials (ClinicalTrial.gov, accessed on 15 October 2021).
| Drug | Status | Study | Target Population | Treatment | Intervention Model |
Number of Partecipants |
|---|---|---|---|---|---|---|
| Blinatumomab | Recruiting | NCT03114865 | Acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (NHLs) | Blinatumomab | Open label, phase 1b/2 study | 64 |
| Blinatumomab | Recruiting | NCT02568553 | Relapsed non-Hodgkin lymphoma | Lenalidomide and blinatumomab | Open label, phase 1 study | 44 |
| Blinatumomab | Active, not recruiting | NCT03072771 | DLBCL post-ASCT | Blinatumomab | Open label, phase 1 study | 14 |
| Blinatumomab | Active, not recruiting | NCT03340766 | Relapsed or refractory DLBCL | Blinatumomab in combination with pembrolizumab | Phase 1b open label study | 31 |
| Glofitamab | Recruiting | NCT04914741 | Younger, higher-risk patients with diffuse large B cell lymphoma | Combination of glofitamab and R-CHOP or pola-RCHP | Open label, multi-centre, phase 1b/2, parallel arm study | 80 |
| Glofitamab | Recruiting | NCT04408638 | Relapsed/refractory diffuse large B-cell lymphoma | Glofitamab in combination with gemcitabine + pxaliplatin | Phase III, open label, multicenter, randomized study | 270 |
| Glofitamab | Recruiting | NCT03467373 | Relapsed/refractory NHLs and untreated diffuse large B-cell lymphoma | Glofitamab in combination with rituximab or pbinutuzumab plus CHOP | Phase 1B, multi-center, dose-finding study | 172 |
| Glofitamab | Recruiting | NCT03075696 | Relapsed/refractory B-cell non-Hodgkin’s lymphoma | Glofitamab as a single agent and in combination with obinutuzumab | Phase 1b/2, multicenter, open label, dose-escalation study | 860 |
| Glofitamab | Recruiting | NCT04077723 | Relapsed/refractory B-cell non-Hodgkin’s lymphoma | Combination with obinutuzumab and glofitamab | Phase 1b/2, open label, dose-escalation study | 362 |
| Glofitamab | Recruiting | NCT03533283 | Relapsed/refractory B-cell non-Hodgkin’s lymphoma | Glofitamab and atezolizumab or polatuzumab vedotin | Open label, single arm, multicenter, dose finding, phase 1b study | 140 |
| Glofitamab | Recruiting | NCT04657302 | Relapsed/refractory diffuse large B-cell lymphoma | Glofitamab as single agent | Phase I, open label, multicenter study | 30 |
| Glofitamab | Recruiting | NCT04980222 | Untreated diffuse large B-cell lymphoma | Glofitamab in combination with rituximab plus CHOP | Phase II, open label, multicenter study | 40 |
| Glofitamab | Recruiting | NCT04889716 | Relapsed or refractory diffuse large B-cell or transformed follicular lymphomas | Glofitamab or mosunetuzumab after CAR T-cells | Open label, phase 2 study | 42 |
| Glofitamab | Recruiting | NCT04703686 | Relapse/refractory lymphomas | Glofitamab after CAR T-cell therapy | Open label, phase 2 study | 78 |
| Glofitamab | Active, not recruiting | NCT04313608 | Relapsed or refractory diffuse large B-cell lymphoma and high-grade large B-cell lymphoma | Glofitamab or mosunetuzumab in combination with gemcitabine plus oxaliplatin | Phase 1b, open label, multicenter study | 20 |
| Epcoritamab | Recruiting | NCT04628494 | Relapsed/refractory diffuse large B-cell lymphoma | Epcoritamab | Randomized, open label, phase 3 trial | 480 |
| Epcoritamab | Recruiting | NCT04663347 | B-cell non-Hodgkin lymphoma | Epcoritamab in combination with other standard of care | Phase 1b/2, open label trial | 270 |
| Epcoritamab | Recruiting | NCT03625037 | Relapsed, progressive, or refractory B-Cell lymphoma | Epcoritamab GEN3013 (DuoBody®-CD3xCD20) | Phase 1/2, open label safety trial | 486 |
| Epcoritamab | Recruiting | NCT04542824 | Relapsed, progressive, or refractory B-cell lymphoma (JAPANESE PATIENTS) | Epcoritamab | Phase 1/2, open label, dose-escalation trial | 73 |
| Odronextamab | Recruiting | NCT03888105 | Relapsed or refractory B-cell non-Hodgkin lymphoma | Odronextamab | Open label, phase 2 study | 512 |
| Odronextamab | Recruiting | NCT02290951 | B-cell non-Hodgkin lymphoma (NHLs) and chronic lymphocytic leukemia (CLL) | Odronextamab | Open label, multi-center phase 1 study | 256 |
| Mosunetuzumab | Recruiting | NCT03671018 | B-cell non-Hodgkin lymphoma | Mosunetuzumab in combination with polatuzumab vedotin | Open label, randomized, multicenter, phase 1b/2 study | 262 |
| Mosunetuzumab | Recruiting | NCT03677154 | Diffuse large B-cell lymphoma following first-line immunochemotherapy or untreated diffuse large B-cell lymphoma | Monotherapy or in combination with polatuzumab vedotin | Phase 1/2 study | 188 |
| Mosunetuzumab | Active, not recruiting | NCT04313608 | Relapsed or refractory diffuse large B-cell lymphoma, and high-grade large B-cell lymphoma | Mosunetuzumab or glofitamab in combination with gemcitabine plus oxaliplatin | Phase 1b, open label, multicenter Study | 20 |
| Mosunetuzumab | Active, not recruiting | NCT03677141 | Untreated diffuse large B-cell lymphoma | Mosunetuzumab in combination with CHOP or CHP-polatuzumab vedotin | Phase 1b/2, open label, multicenter, randomized, Controlled study | 160 |
| Mosunetuzumab | Not yet recruiting | NCT04792502 | Untreated FL or MZL | Mosunetuzumab with lenalidomide augmentation | Phase 2, open label study | 52 |
| Mosunetuzumab | Not yet recruiting | NCT04889716 | Relapsed or refractory diffuse large B-cell or transformed follicular lymphomas | Mosunetuzumab or glofitamab after CAR T-cells | Phase 2 study | 42 |
| Mosunetuzumab | Recruiting | NCT02500407 | Relapsed or refractory B-cell NHLs and CLL | Mosunetuzumab as a single agent and combined with atezolizumab | Open label, multicenter, phase 1/2 study | 836 |